Finally, some data.
Here is where Azer-cel + chemotherapy compares to some of the other Allogeneic CAR-T therapies in combination with chemotherapy.
In comparison to peer allogeneic CAR T therapies, Azer-cel appears to be underperrforming as well as lagging behind in clinical development. With so many competitors, the risk of clinical and moreso commercial success is very high.
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00554-0/fulltext
https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.7025
https://www.sciencedirect.com/science/article/pii/S0006497121022990
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32334-5/abstract
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.2517
https://www.nature.com/articles/s41591-023-02785-8
Finally, some data.Here is where Azer-cel + chemotherapy...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.6¢ |
Change
0.001(2.22%) |
Mkt cap ! $342.1M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $906.2K | 19.67M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 20 | 9543864 | 4.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.6¢ | 1266571 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |